Donanemab: A Promising Breakthrough in Alzheimer's Treatment

The final results of the TRAILBLAZER-ALZ 2 study show that donanemab, a disease-modifying therapy for early symptomatic Alzheimer's disease (AD), significantly slows cognitive and functional decline in patients with amyloid-positive AD, regardless of their baseline level of tau. The study found that donanemab reduced amyloid plaque by 84% compared to placebo after 18 months of treatment. Patients who achieved amyloid plaque clearance could stop treatment and still experience lasting benefits. The results support the importance of early diagnosis and treatment for AD, and donanemab has been submitted to the FDA for approval.